Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City.

Citation metadata

Publisher: Frontiers Research Foundation
Document Type: Article
Length: 473 words
Lexile Measure: 1710L

Document controls

Main content

Article Preview :

Author(s): Oscar Arturo Lozano-Cruz, José Và­ctor Jiménez, Antonio Olivas-Martinez, Edgar Ortiz-Brizuela, José Luis Cà¡rdenas-Fragoso, Daniel Azamar-Llamas, Sergio Rodrà­guez-Rodrà­guez, Jorge Carlos Oseguera-Moguel, Joel Dorantes-Garcà­a, Clemente Barrà³n-Magdaleno, Aldo C Cà¡zares-Diazleal, Carla Marina Romà¡n-Montes, Karla Marà­a Tamez-Torres, Bernardo Alfonso Martà­nez-Guerra, Alfonso Gulias-Herrero, Marà­a Fernanda Gonzà¡lez-Lara, Alfredo Ponce-de-Leà³n-Garduà±o, David Kershenobich-Stalnikowitz, José Sifuentes-Osornio

<bold>Background:</bold> Antimalarial drugs were widely used as experimental therapies against COVID-19 in the initial stages of the pandemic. Despite multiple randomized controlled trials demonstrating unfavorable outcomes in both efficacy and adverse effects, antimalarial drugs are still prescribed in developing countries, especially in those experiencing recurrent COVID-19 crises (India and Brazil). Therefore, real-life experience and pharmacovigilance studies describing the use and side effects of antimalarials for COVID-19 in developing countries are...

Source Citation

Source Citation   

Gale Document Number: GALE|A663969204